What to Know About Acromegaly Diagnostic Criteria

Acromegaly is diagnosed through a combination of clinical features and laboratory tests. Persistent elevation of insulin-like growth factor 1 (IGF-1) suggests excess growth hormone. Confirmation often relies on a failure of growth hormone to suppress during an oral glucose tolerance test. Imaging, typically pituitary MRI, helps identify an adenoma, while differential assessment rules out alternative sources of growth hormone or IGF-1 excess.

Overview of Acromegaly Diagnostic Criteria

Acromegaly is characterized by chronic excess of growth hormone (GH) leading to increased insulin-like growth factor 1 (IGF-1). Diagnostic criteria center on demonstrating biochemical evidence of GH excess, followed by localization of the source, most commonly a pituitary adenoma. The core elements include:

  • Clinical features consistent with chronic GH excess.
  • Elevated age- and sex-adjusted IGF-1 concentration on a validated assay.
  • Failure of GH to suppress during an oral glucose tolerance test (OGTT), when needed for confirmation.
  • Imaging, typically pituitary magnetic resonance imaging (MRI), to identify a lesion.
  • Additional testing to distinguish pituitary from ectopic sources of GH or growth hormone–releasing hormone (GHRH).

Because GH secretion is pulsatile, random GH measurements are unreliable for diagnosis. IGF-1, which reflects integrated GH exposure over time, is the preferred initial biochemical marker.

Recognizing Clinical Features That Raise Suspicion

Diagnostic workup is usually considered when characteristic features are present. Common manifestations include:

  • Acral changes: enlargement of hands and feet, increased ring or shoe size, and thickened skin.
  • Facial changes: frontal bossing, prognathism, widened nasal bridge, and coarse facial features.
  • Soft tissue and organ overgrowth: macroglossia, deepened voice, snoring or sleep apnea, and organomegaly.
  • Musculoskeletal symptoms: arthralgia, carpal tunnel syndrome, spinal stenosis, and reduced joint mobility.
  • Metabolic and systemic effects: insulin resistance or diabetes mellitus, hypertension, cardiomyopathy, hyperhidrosis, and colon polyps.
  • Headache and visual field defects, particularly bitemporal hemianopsia, when a macroadenoma exerts mass effect.

The presence of multiple features, especially in a gradual pattern, increases the likelihood of acromegaly and supports targeted testing.

Biochemical Screening: IGF-1 as the Cornerstone

Age- and sex-normalized IGF-1 concentration is the primary screening test. Key points about IGF-1 in this context:

  • Elevated IGF-1 above the upper limit of normal for age and sex is a strong indicator of GH excess.
  • IGF-1 exhibits low intra-day variability and is stable in the fasting and fed state, making it preferable to random GH measurement for screening.
  • Reference intervals and assay standardization vary among laboratories. Interpretation should rely on the assay-specific reference range and consider known analytical differences across platforms.
  • Borderline or equivocal elevations may warrant repeat testing, particularly if preanalytical factors could alter results.

Conditions and factors that can modify IGF-1 levels include poorly controlled diabetes, hepatic or renal dysfunction, malnutrition, thyroid dysfunction, high-dose oral estrogen therapy, pregnancy, and adolescence. These influences can yield false-positive or false-negative impressions if not accounted for.

Confirmatory Testing: GH Suppression During OGTT

When IGF-1 is clearly elevated and clinical features are typical, many diagnostic pathways proceed to GH suppression testing to confirm autonomous GH secretion. The oral glucose tolerance test evaluates physiologic suppression of GH:

  • Test principle: In healthy individuals, oral glucose suppresses GH secretion. Failure of GH to suppress suggests acromegaly.
  • Procedure overview: After an overnight fast, baseline GH is measured, followed by administration of a standard glucose load. Serial GH measurements are obtained over the next two hours to capture nadir GH.
  • Interpretation: Commonly cited nadir GH cutoffs range from less than 0.4 to less than 1.0 ng/mL, depending on the assay’s sensitivity and calibration. A nadir GH above an assay-appropriate cutoff supports a diagnosis of acromegaly when IGF-1 is elevated.

Assay selection matters. With modern ultrasensitive GH assays, lower cutoffs (for example, around 0.4 ng/mL) are often used. Biotin interference, heterophile antibodies, and macro-GH can confound results; laboratories may apply methods to minimize these effects.

Imaging the Pituitary and Beyond

Once biochemical data indicate GH excess, imaging is used to localize the source:

  • Pituitary MRI with contrast is the preferred modality to detect microadenomas and macroadenomas, define size and invasiveness, and assess cavernous sinus involvement.
  • If MRI is negative or equivocal and biochemical evidence remains strong, additional steps may include repeat high-resolution pituitary imaging, dynamic sequences, or evaluation for ectopic GHRH or, rarely, ectopic GH secretion.
  • Computed tomography (CT) or MRI of the chest and abdomen may be considered when ectopic secretion is suspected based on biochemical and clinical clues.

Imaging findings are interpreted in conjunction with hormone results. Nonfunctioning pituitary incidentalomas can coexist and require careful correlation with IGF-1 and GH suppression data.

Distinguishing Pituitary From Ectopic Sources

Most cases result from a pituitary somatotroph adenoma. Less commonly, excess GH results from:

  • Ectopic GHRH secretion from neuroendocrine tumors (for example, pancreatic or bronchial). This drives pituitary hyperplasia and secondary GH excess.
  • Rare ectopic GH–secreting tumors.

Clues suggesting ectopic GHRH include diffuse pituitary enlargement rather than a discrete adenoma on MRI, elevated plasma GHRH, and identification of a neuroendocrine tumor on imaging. Measuring GHRH is not routine but can be informative in atypical cases.

Special Situations Affecting Interpretation

Several scenarios complicate biochemical interpretation:

  • Diabetes and hyperglycemia: Elevated glucose can blunt GH suppression; inadequate glycemic control may affect both IGF-1 and GH dynamics.
  • Estrogen therapy: Oral estrogens can reduce hepatic IGF-1 production and alter GH feedback, potentially lowering IGF-1 and elevating GH; transdermal routes have less impact.
  • Liver or kidney disease: Altered metabolism and binding proteins can shift IGF-1 levels.
  • Malnutrition and severe illness: These states can lower IGF-1, potentially obscuring acromegaly.
  • Pregnancy: Physiologic increases in GH variants and placental hormones make standard criteria difficult to apply; IGF-1 and GH assays may not reflect typical dynamics during gestation.
  • Adolescence: Excess GH before epiphyseal closure leads to gigantism; diagnostic principles are similar but must account for pubertal reference ranges.

In each case, contextual clinical information and appropriate reference intervals are essential to accurate assessment.

Cytokines, Binding Proteins, and Assay Considerations

IGF-1 circulates bound to IGF-binding proteins. Assays attempt to dissociate these complexes to measure total IGF-1. Preanalytical and analytical issues include:

  • Binding protein interference and incomplete dissociation in some methods.
  • Calibration differences across platforms leading to variability between laboratories.
  • Biotin-streptavidin assay interference when high-dose biotin supplements are used. For GH, immunoassays target specific isoforms; not all assays recognize GH variants equally. Use of the same laboratory and assay for serial testing improves consistency.

Putting the Criteria Together: A Common Diagnostic Framework

A typical diagnostic framework integrates steps in a logical sequence:

  • Suspicion based on compatible clinical features.
  • Measurement of age- and sex-adjusted IGF-1 using a validated, locally referenced assay.
  • If IGF-1 is elevated, performance of an OGTT to assess GH suppression, especially when results are borderline or when documentation of autonomous GH secretion is desired.
  • Pituitary MRI to identify and characterize an adenoma or to evaluate for pituitary hyperplasia.
  • Additional biochemical testing when the source is unclear, including consideration of GHRH measurement and imaging for potential ectopic sources.

This approach accommodates the strengths and limitations of each test and supports a diagnosis based on convergent evidence rather than a single data point.

Differential Diagnosis and Conditions That Mimic Acromegaly

Several conditions may resemble acromegaly clinically or biochemically:

  • Hypothyroidism and other endocrine disorders that cause soft tissue swelling or facial changes.
  • Paget disease of bone or genetic skeletal dysplasias causing changes in bone structure.
  • Medication effects, such as anabolic steroids, causing acral or facial changes.
  • Pseudoacromegaly, in which features mimic acromegaly but IGF-1 is normal and GH suppresses normally.

Careful correlation of clinical signs with IGF-1 and OGTT results helps differentiate these entities.

Role of Ancillary Testing After Biochemical Confirmation

Once GH excess is established and a lesion is identified, additional evaluations often document associated comorbidities and hormone function for comprehensive care planning:

  • Assessment of other pituitary axes to identify hypopituitarism or hyperprolactinemia.
  • Cardiometabolic evaluation, including glucose tolerance, blood pressure, and cardiac structure and function.
  • Colonoscopic screening schedules may be influenced by acromegaly due to a higher prevalence of colonic polyps.

While these assessments do not define the initial diagnostic criteria, they provide context for the broader health impact and guide longitudinal follow-up.

Key Takeaways

  • Elevated, age- and sex-adjusted IGF-1 is the primary biochemical hallmark of acromegaly.
  • Failure of GH suppression during an OGTT provides confirmatory evidence, with specific nadir GH thresholds dependent on assay sensitivity.
  • Pituitary MRI localizes the lesion in most cases; ectopic GHRH should be considered when imaging is negative or shows diffuse enlargement.
  • Clinical context, comorbid conditions, and assay-specific factors are crucial for accurate interpretation, particularly in special populations and borderline cases.